Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood [Blood] Journal article | | Title | Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). | | Author(s) | Kroger N, Holler E, Kobbe G, Bornhaeuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T, Kvasnicka HM, Thiele J, Brand R, Zander AR, Niederwieser D, de Witte TM | | Institution | University Hospital Hamburg-Eppendorf, Germany. | | Source | Blood 2009 Oct 7. | | Abstract | From 2002 to 2007, 103 patients with primary myelofibrosis or post ET/PV myelofibrosis and a median age of 55 years (range, 32--68) were included in a prospective multicenter phase II trial to determine efficacy of a busulfan (10 mg/kg) /fludarabine (180mg/m(2)) -based reduced-intensity conditioning regimen (RIC) followed by allogeneic stem cell transplantation from related (n=33) or unrelated donors (n=70). All but two patients (2%) showed leukocyte and platelet engraftment after a median of 18 and 22 days, respectively. Acute graft-versus-host disease (GvHD) grade II to IV occurred in 27% and chronic GvHD in 43% of the patients. Cumulative incidence of non-relapse mortality at one year was 16% (95% CI: 9--23%) and significantly lower for patients with a completely matched donor (12% vs. 38%) (p=0.003). The cumulative incidence of relapse at three years was 22% (95% CI: 13--31%), and was influenced by Lille-risk profile (low: 14%, intermediate: 22%, and high: 34%) (p=0.02). The estimated five-year event-free and overall survival was 51% and 67%, respectively. In a multivariate analysis, age > 55 years (HR: 2.70; p=0.02) and HLA-mismatched donor (HR; 3.04; p=0.006) remained significant factors for survival. The study was registered at www.clinicaltrials.gov under: NCT 00599547. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19812383 |
|
|
| |
Advertise on this site.
| | |
|
